Insider Buying: Longeveron Inc. (NASDAQ:LGVN) Director Purchases 31,915 Shares of Stock

Longeveron Inc. (NASDAQ:LGVNGet Free Report) Director Rock Soffer bought 31,915 shares of Longeveron stock in a transaction dated Thursday, April 11th. The stock was acquired at an average cost of $2.35 per share, for a total transaction of $75,000.25. Following the completion of the acquisition, the director now directly owns 208,534 shares in the company, valued at $490,054.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Longeveron Price Performance

Shares of LGVN traded down $0.33 on Friday, hitting $1.69. The company’s stock had a trading volume of 494,120 shares, compared to its average volume of 820,154. The company has a market capitalization of $4.24 million, a PE ratio of -0.17 and a beta of 0.21. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.50 and a quick ratio of 1.50. Longeveron Inc. has a fifty-two week low of $1.62 and a fifty-two week high of $44.00. The company has a 50 day moving average price of $4.32 and a 200 day moving average price of $12.41.

Longeveron (NASDAQ:LGVNGet Free Report) last announced its earnings results on Tuesday, February 27th. The company reported ($2.50) EPS for the quarter, missing the consensus estimate of ($2.10) by ($0.40). The business had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.21 million. Longeveron had a negative return on equity of 209.14% and a negative net margin of 3,020.17%. On average, research analysts anticipate that Longeveron Inc. will post -8.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of LGVN. Vanguard Group Inc. lifted its holdings in Longeveron by 6.1% during the 3rd quarter. Vanguard Group Inc. now owns 184,267 shares of the company’s stock worth $682,000 after buying an additional 10,600 shares in the last quarter. Northern Trust Corp acquired a new position in Longeveron during the 2nd quarter worth $63,000. State Street Corp acquired a new position in Longeveron during the 2nd quarter worth $88,000. Geode Capital Management LLC lifted its holdings in Longeveron by 78.6% during the 2nd quarter. Geode Capital Management LLC now owns 66,392 shares of the company’s stock worth $224,000 after buying an additional 29,212 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in Longeveron during the 4th quarter worth $44,000. 10.01% of the stock is owned by institutional investors and hedge funds.

Longeveron Company Profile

(Get Free Report)

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors.

Featured Articles

Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.